Here we found that the use of a gliptins, more specifically sitagliptin, does not induce significant appearance of anti-BP180 autoantibodies but modulates levels of SDF-1α decreasing its total serum concentration in both T2D and BP patients. Here, CXCL12 is linked to type 2 diabetes mellitus.